fig4
![Percutaneous treatment of mitral valve disease: repair <i>vs.</i> replacement](https://image.oaes.cc/3a80017a-852d-46cf-924f-3fa5a8dcbd7b/4049.fig.4.jpg)
Figure 4. (1) Percutaneous mitral valve anchoring systems: (a) Atrial flange and ventricle tethers; (b) atrial flange and native valve anchors; (c) atrial and ventricle flanges; (d) subannular hooks; and (e) atrial cage. Adapted from Preston-Maher et al.[46]. (2) Transcatheter mitral valve replacement devices. (A) CardiAQ/EVOQUE (Edwards Lifesciences Inc); (B) Tiara (Neovasc Inc, Canada); (C) Tendyne (Abbott Inc); (D) Intrepid (Medtronic Inc); (E) Caisson (LivaNova, UK); (F) HighLife Bioprosthesis and Subannular Implant (HighLife SAS, France); (G) SAPIEN M3 (Edwards Lifesciences Inc); and (H) Cardiovalve (Cardiovalve, Israel). Adapted from Testa et al.[47].